Cofactor Genomics, a Saint Louis, MO-based provider of RNA products and applications, acquired Narus Biotechnologies, a San Francisco, CA-based biomarker development company.
The amount of the deal was not disclosed.
Led by Raman Talwar, newly appointed Director of Diagnostic Development at Cofactor, Narus Biotechnologies focuses on creating RNA diagnostic tests for neurological diseases that can help inform therapeutic selection for patients with Multiple Sclerosis, Alzheimer’s and Parkinson’s.
Led by Dr. Jarret Glasscock, CEO, Cofactor Genomics uses RNA to diagnose disease. The company, which is backed by Y Combinator, works with pharma companies to enable early diagnostic tests in neurological diseases and cancer and will leverage the team Narus (and its San Francisco presence) to accelerate its RNA-based diagnostic roadmap capabilities.